Roche (OTCMKTS:RHHBY – Get Rating) had its price target dropped by research analysts at Credit Suisse Group from CHF 370 to CHF 350 in a report issued on Thursday, The Fly reports. The brokerage presently has a “neutral” rating on the stock.
A number of other equities analysts also recently weighed in on the stock. Jefferies Financial Group downgraded shares of Roche from a “buy” rating to a “hold” rating in a report on Friday, May 13th. Deutsche Bank Aktiengesellschaft cut Roche from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Morgan Stanley lowered their price objective on Roche from CHF 395 to CHF 370 and set an “equal weight” rating on the stock in a research note on Thursday, May 12th. JPMorgan Chase & Co. lowered their price objective on Roche from CHF 390 to CHF 370 and set a “neutral” rating on the stock in a research note on Friday, March 11th. Finally, Barclays boosted their price objective on Roche from CHF 415 to CHF 450 in a research note on Thursday, April 14th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $318.40.
Shares of OTCMKTS:RHHBY traded down $0.03 during midday trading on Thursday, reaching $40.34. The company had a trading volume of 4,268,431 shares, compared to its average volume of 2,719,743. The company’s 50 day moving average price is $47.78 and its 200 day moving average price is $48.66. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.93 and a quick ratio of 0.73. Roche has a 52-week low of $39.32 and a 52-week high of $53.86.
Roche Company Profile (Get Rating)
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
- Get a free copy of the StockNews.com research report on Roche (RHHBY)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.